

SANDERLING V LTD PARTNERSHIP
 Form 3
 March 18, 2008

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Sanderling Venture Partners IV, L.P.			(Month/Day/Year)	CARDIONET INC [BEAT]	
(Last)	(First)	(Middle)	03/18/2008		
400 SOUTH EL CAMINO REAL, SUITE 1200			4. Relationship of Reporting Person(s) to Issuer		
(Street)			(Check all applicable)		
SAN MATEO, CA 94402			<input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below)		
(City)	(State)	(Zip)	5. If Amendment, Date Original Filed(Month/Day/Year)		
			6. Individual or Joint/Group Filing(Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable Expiration Date	Title Amount or Number of			

Edgar Filing: SANDERLING V LTD PARTNERSHIP - Form 3

				Shares		or Indirect (1) (Instr. 5)	
Series C Convertible Preferred Stock	Â <u>(1)</u>	Â <u>(1)</u>	Common Stock	53,721	\$ <u>(1)</u>	I	See footnotes <u>(2)</u>
Series C Convertible Preferred Stock	Â <u>(1)</u>	Â <u>(1)</u>	Common Stock	223,839	\$ <u>(1)</u>	I	See footnotes <u>(3)</u>
Series C Convertible Preferred Stock	Â <u>(1)</u>	Â <u>(1)</u>	Common Stock	60,374	\$ <u>(1)</u>	I	See footnotes <u>(4)</u>
Series C Convertible Preferred Stock	Â <u>(1)</u>	Â <u>(1)</u>	Common Stock	369,209	\$ <u>(1)</u>	I	See footnotes <u>(5)</u>
Series D Convertible Preferred Stock	Â <u>(6)</u>	Â <u>(6)</u>	Common Stock	11,281	\$ <u>(6)</u>	I	See footnotes <u>(2)</u>
Series D Convertible Preferred Stock	Â <u>(6)</u>	Â <u>(6)</u>	Common Stock	47,006	\$ <u>(6)</u>	I	See footnotes <u>(3)</u>
Series D Convertible Preferred Stock	Â <u>(6)</u>	Â <u>(6)</u>	Common Stock	12,679	\$ <u>(6)</u>	I	See footnotes <u>(4)</u>
Series D Convertible Preferred Stock	Â <u>(6)</u>	Â <u>(6)</u>	Common Stock	77,534	\$ <u>(6)</u>	I	See footnotes <u>(5)</u>
Warrants to Purchase Series D-1 Convertible Preferred Stock	Â <u>(7)</u>	Â <u>(8)</u>	Common Stock	27,844	\$ 3.5	I	See footnotes <u>(2)</u>
Warrants to Purchase Series D-1 Convertible Preferred Stock	Â <u>(7)</u>	Â <u>(8)</u>	Common Stock	116,019	\$ 3.5	I	See footnotes <u>(3)</u>
Warrants to Purchase Series D-1 Convertible Preferred Stock	Â <u>(7)</u>	Â <u>(8)</u>	Common Stock	31,293	\$ 3.5	I	See footnotes <u>(4)</u>
Warrants to Purchase Series D-1 Convertible Preferred Stock	Â <u>(7)</u>	Â <u>(8)</u>	Common Stock	191,369	\$ 3.5	I	See footnotes <u>(5)</u>
Mandatorily Convertible Preferred Stock	Â <u>(9)</u>	Â <u>(9)</u>	Common Stock	170	\$ <u>(9)</u>	I	See footnotes <u>(2)</u>
Mandatorily Convertible Preferred Stock	Â <u>(9)</u>	Â <u>(9)</u>	Common Stock	707	\$ <u>(9)</u>	I	See footnotes <u>(3)</u>
Mandatorily Convertible Preferred Stock	Â <u>(9)</u>	Â <u>(9)</u>	Common Stock	191	\$ <u>(9)</u>	I	See footnotes <u>(4)</u>
Mandatorily Convertible Preferred Stock	Â <u>(9)</u>	Â <u>(9)</u>	Common Stock	1,165	\$ <u>(9)</u>	I	See footnotes <u>(5)</u>

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Sanderling Venture Partners IV, L.P. 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO, CA 94402	Â	Â X	Â	Â
SANDERLING V BETEILIGUNGS GMBH & CO KG 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO, CA 94402	Â	Â X	Â	Â
SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO, CA 94402	Â	Â X	Â	Â
Sanderling Venture Partners V Co Investment Fund, LP 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO, CA 94402	Â	Â X	Â	Â
SANDERLING V LTD PARTNERSHIP 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO, CA 94402	Â	Â X	Â	Â

Signatures

See Ex. 99.1 03/17/2008

__Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Series C Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of one share of Common Stock for every two shares of Series C Preferred Stock, for no additional consideration.

(2) By Sanderling V Beteiligungs GmbH & Co KG. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling V Beteiligungs GmbH & Co KG and has voting and investment power over the shares held by Sanderling V Beteiligungs GmbH & Co KG. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

(3) By Sanderling V Biomedical Co-Investment Fund L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling V Biomedical Co-Investment Fund L.P and has voting and investment power over the shares held by Sanderling V Biomedical Co-Investment Fund L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

(4) By Sanderling V Limited Partnership. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling V Limited Partnership and has voting and investment power over the shares held by Sanderling V Limited Partnership. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Edgar Filing: SANDERLING V LTD PARTNERSHIP - Form 3

- (5) By Sanderling Venture Partners V Co-Investment Fund, L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling Venture Partners V Co-Investment Fund, L.P and has voting and investment power over the shares held by Sanderling Venture Partners V Co-Investment Fund, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- (6) Series D Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of one share of Common Stock for every two shares of Series D Preferred Stock, for no additional consideration.
- (7) Warrants became exercisable on March 8, 2007.
- (8) Warrants to purchase Series D-1 Convertible Preferred will be automatically net exercised immediately prior to the closing of the Issuer's initial public offering. Series D-1 Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of one share of Common Stock for every two shares of Series D-1 Preferred Stock, for no additional consideration.
- (9) Mandatorily Convertible Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of one share of Mandatorily Convertible Preferred Stock for every 66.88 shares of Common Stock, for no additional consideration.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.